{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:27:40Z","timestamp":1767979660931,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2495,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2001,9,7]]},"abstract":"<jats:p>Despite the intensive clinical use of 1\u2010deamino\u20108\u2010<jats:sc>D<\/jats:sc>\u2010arginine vasopressin (desmopressin; DDAVP) for 20\u2003years, its mechanism of action is still not completely explained. It has been proposed that DDAVP stimulates release of a \u2018second messenger\u2019 which in turn stimulates release of von Willebrand factor (vWF) from endothelial cells. Platelet\u2010activating factor (PAF) and interleukin (IL)\u20106 were individually proposed to be mediators for haemostatic action. The aim of this study was to investigate cellular\u2010based PAF levels in patients with haemophilia A (HA) and von Willebrand disease (vWD) before and after DDAVP treatment and also to look for any probable relationship between the haemostatic response of DDAVP and cellular PAF activities. In total, 20 patients (11 HA and nine vWD) were enrolled in the study. DDAVP was given subcutaneously as a single dose (0.3\u2003\u03bcg\u2003kg<jats:sup>\u20131<\/jats:sup>). Ten patients responded to DDAVP and were defined as the \u2018able group\u2019 (four mild HA, six type 1 vWD). The remaining 10 patients did not respond to DDAVP and were defined as the \u2018unable group\u2019 (seven severe HA, three type 3 vWD). Released (extracellular) and intracellular (intraleucocyte) PAF levels under the stimulation of specific agents (A23187 and Zymosan) were measured by high\u2010performance liquid chromatography and radioimmunoassay. Extracellular and intracellular PAF activities were not detected without stimulation in healthy children whereas significantly higher PAF levels were found in the patients (extracellular: 37.5\u2003\u00b1\u200334.4\u2003ng per 10<jats:sup>7<\/jats:sup> cells; intracellular: 24.8\u2003\u00b1\u200323.5\u2003ng per 10<jats:sup>7<\/jats:sup> cells; <jats:italic>P<\/jats:italic>=0.0001). Intracellular PAF levels obtained from <jats:italic>in vitro<\/jats:italic> unstimulated cells were significantly higher in DDAVP\u2010responsive (able) patients in comparison to DDAVP\u2010unresponsive (unable) patients (52.1\u2003\u00b1\u200318.5 vs. 28.9\u2003\u00b1\u20038.0\u2003ng per 10<jats:sup>7<\/jats:sup>cells). After <jats:italic>in vitro<\/jats:italic> stimulation by A23187, intracellular PAF activities were significantly higher in patients than in controls (209.3\u2003\u00b1\u200326.1 vs. 172\u2003\u00b1\u200318.1\u2003ng per 10<jats:sup>7<\/jats:sup> cells). Intracellular PAF levels obtained from <jats:italic>in vitro<\/jats:italic> stimulated cells by A23187 were also significantly higher in the \u2018able\u2019 patients in comparison to the \u2018unable\u2019 patients (277\u2003\u00b1\u200343.5 vs. 225\u2003\u00b1\u200330\u2003ng per 10<jats:sup>7<\/jats:sup>cells). In conclusion, cellular PAF activities are significantly higher in patients with HA and vWD. We also suggest that PAF, especially intracellular PAF mediates intracellular signalling and may be one of the important mediators for the haemostatic response of DDAVP.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2001.00535.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:06:27Z","timestamp":1047423987000},"page":"482-489","source":"Crossref","is-referenced-by-count":5,"title":["Intraleucocyte platelet\u2010activating factor levels in desmopressin\u2010treated patients with haemophilia A and von Willebrand disease"],"prefix":"10.1111","volume":"7","author":[{"given":"K.","family":"Kavakli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"H\u00fcseyinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"\u00c7oker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Aydinok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Nisli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2515"},{"key":"e_1_2_6_3_2","first-page":"276","article-title":"Response to 1\u2010deamino\u20108\u2010D\u2010arginine vasopressin in von Willebrand\u2019s disease","volume":"24","author":"Lusher JM","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996055"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01814.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041540307"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0037-1613996","article-title":"Local and systemic effects of intra\u2010arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin\u20106","volume":"84","author":"Newby DE","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.110.2.529"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1995.tb00894.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1055\/s-0037-1614548","article-title":"Plasma platelet\u2010activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand\u2019s disease","volume":"81","author":"Kavakli K","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-0179-8_47"},{"key":"e_1_2_6_12_2","first-page":"47","article-title":"The bioregulatory role of PAF in intra\u2010cellular process and cell\u2013cell interactions","volume":"63","author":"Kulikov VI","year":"1998","journal-title":"Biochemistry"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)83507-0"},{"key":"e_1_2_6_14_2","first-page":"61","article-title":"High performance liquid chromatography technique for determination of PAF in biological media","volume":"1","author":"Huseyinof A","year":"1994","journal-title":"Balkan J Clin Lab"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200005000-00017"},{"key":"e_1_2_6_16_2","first-page":"97","article-title":"Prospective in PAF research","volume":"39","author":"Braquet P","year":"1987","journal-title":"Pharm Rev"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.155.1.316","article-title":"LPS binding protein and CD14 modulate the synthesis of PAF by human monocytes and endothelial cells stimulates with LPS","volume":"155","author":"Cannusbi G","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.1998.tb01403.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199611)53:3<158::AID-AJH2>3.0.CO;2-Y"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113818"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199402000-00009"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/374549a0"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118733"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-0037-1615214","article-title":"A mutation in plasma Platelet\u2010activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension","volume":"80","author":"Yoshida H","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00355.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(83)90326-2"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00535.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00535.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2001.00535.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:52:43Z","timestamp":1697370763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2001.00535.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,7]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,9,7]]}},"alternative-id":["10.1046\/j.1365-2516.2001.00535.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00535.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,7]]}}}